Adicet Bio Appoints Nick Harvey as Chief Financial Officer
September 16, 2020 07:00 ET
|
Adicet Bio, Inc.
MENLO PARK, Calif. and BOSTON, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for...
Adicet Bio to Present at the Cantor Virtual Global Healthcare Conference
September 15, 2020 16:10 ET
|
Adicet Bio, Inc.
MENLO PARK, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and...
Adicet Announces Completion of Merger with resTORbio
September 15, 2020 08:55 ET
|
resTORbio, Inc.
- Adicet Emerges as a Leading Allogeneic Gamma Delta T Cell Therapy Company Focused on Oncology - -Trading to Commence on September 16, 2020 on The Nasdaq Global Market Under Ticker Symbol “ACET”- ...
resTORbio Provides Corporate Update and Reports Second Quarter 2020 Financial Results
July 30, 2020 07:30 ET
|
resTORbio, Inc.
BOSTON, July 30, 2020 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or...
resTORbio Announces an Award from the National Institute on Aging to Fund a Pilot Study of RTB101 as COVID-19 Prophylaxis in Older Adults
July 28, 2020 07:00 ET
|
resTORbio, Inc.
BOSTON, July 28, 2020 (GLOBE NEWSWIRE) -- resTORbio resTORbio, Inc. (Nasdaq: TORC) today announced the award from the National Institute on Aging to fund a randomized, double-blind,...
resTORbio Announces Initiation of Study to Evaluate if Antiviral Prophylaxis with RTB101 Reduces the Severity of COVID-19 in Nursing Home Residents
May 28, 2020 07:00 ET
|
resTORbio, Inc.
BOSTON, May 28, 2020 (GLOBE NEWSWIRE) -- resTORbio (Nasdaq: TORC) today announced the initiation of a randomized, double-blind, placebo-controlled trial of RTB101, an investigational...
resTORbio Provides Corporate Update and Reports First Quarter 2020 Financial Results
May 07, 2020 07:30 ET
|
resTORbio, Inc.
BOSTON, May 07, 2020 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or...
resTORbio to Host its 2020 Annual Shareholder Meeting Virtually on June 3, 2020
April 30, 2020 16:01 ET
|
resTORbio, Inc.
BOSTON, April 30, 2020 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC) today announced that due to the public health impact of the coronavirus pandemic and to prioritize the health and well-being...
resTORbio and Adicet Bio Announce Merger Agreement to Advance Allogeneic Gamma Delta CAR-T Cell Therapy Technology
April 29, 2020 07:00 ET
|
resTORbio, Inc.
Combined Company to Focus on Adicet’s Technology and Continue Operations as “Adicet Bio” Adicet’s lead asset ADI-001 is an allogeneic gamma delta T cell therapy expressing a chimeric antigen receptor...
resTORbio Announces Delay of its Ongoing Phase 1b/2a trial of RTB101 in Patients with Parkinson’s Disease Due to COVID-19 Level 4 Alert in New Zealand
April 03, 2020 08:00 ET
|
resTORbio, Inc.
BOSTON, April 03, 2020 (GLOBE NEWSWIRE) -- resTORbio (Nasdaq: TORC) today announced that it will postpone enrollment in the fifth cohort of its ongoing Phase 1b/2a trial of RTB101, an orally...